Medical device giant Boston Scientific has laid the groundwork to shift $15 billion (€12.8 billion) in dividends out of the country following a major corporate restructuring, according to company filings. An Irish-based entity holding more than $20 billion in intellectual property completed the balance sheet reorganization in March, unlocking substantial capital distributions to its immediate Dutch parent and ultimate US headquarters.
Corporate Restructuring Unlocks $15 Billion Dividend Pipeline
A note attached to new accounts for Boston Scientific Medical Device Limited reveals that the reorganisation transferred $15 billion from the company’s reserves straight into its profit-and-loss reserve. According to company documents, this accounting shift allows these amounts to be distributed upstream to the Netherlands and onward to the United States. The Irish entity was originally established in 2017.
In recent financial years, the company has ramped up its payout schedule. Last year, the firm disbursed an $800 million dividend to its Dutch parent. Regulatory filings show this latest transfer brings total payouts to more than $3.7 billion since 2023.
Intellectual Property Transfers and Amortisation Charges
Boston Scientific Medical Device Limited has held tens of billions of dollars in intellectual property since 2019, when the broader group shifted $34.8 billion worth of IP into the Irish operation. Revenues at the firm, generated from IP licensing and medical-device sales, climbed from $1.4 billion to $9.3 billion over the period, according to the accounts.
Despite surging revenues, the entity recorded annual losses ranging between $497 million and $1.6 billion each year. These losses stem from substantial amortisation charges applied to its intellectual property. Multinationals operating in Ireland frequently use this standard accounting practice to reduce the book value of intangible assets over their expected useful life, which in turn helps minimise local tax liabilities. The company has amortised its IP value by at least $2 billion annually since 2019, leaving a carrying value of $23 billion at the end of 2025.
Did you know? Boston Scientific’s Irish manufacturing arm reported an 18 percent increase in turnover to $2.07 billion, alongside a 22 percent jump in pretax profits to $135.7 million, according to separate accounts published concurrently with the IP holding company filings.
Expansion and Manufacturing Footprint in Ireland
Boston Scientific first established its Irish presence in 1994 and has steadily expanded through new facilities and local acquisitions. The company’s domestic manufacturing operations now produce more than 30 million medical devices every year for patients across the globe, according to corporate disclosures.
The multinational employed more than 7,000 people in the Republic last year. These workers are distributed across major operational bases located in Galway, Clonmel, and Cork. Demonstrating ongoing commitment to the region, the group announced plans earlier this year to invest an additional €75 million into its Irish business infrastructure.
Frequently Asked Questions
How much money is Boston Scientific positioned to move out of Ireland?
Company filings show that Boston Scientific has restructured its balance sheet to allow the shift of $15 billion (€12.8 billion) in dividends out of the country.
What role does the Irish entity play in the broader corporate structure?
Boston Scientific Medical Device Limited holds tens of billions of dollars in intellectual property and handles IP licensing and device sales, generating billions in revenue.
How many people does Boston Scientific employ in Ireland?
The company employed more than 7,000 people in the Republic last year across manufacturing and operational facilities in Galway, Clonmel, and Cork.
Want to stay informed on corporate finance and medtech industry developments? Leave a comment below or explore our archive for more in-depth reporting.